Leukemia Clinical Trials in Portland

Showing 461-480 of 793 trials

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

NCT02381314

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

MelanomaNon Small Cell Lung Cancer

MacroGenics24 participantsStarted Mar 2015

Los Angeles, California, United States • New Haven, Connecticut, United States • Miami Beach, Florida, United States +7 more locations

COMPLETEDPhase 3< 1 mile

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00369317

This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

Childhood Acute Basophilic LeukemiaChildhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)+12 more

Children's Oncology Group205 participantsStarted Mar 2007

Phoenix, Arizona, United States • Downey, California, United States • Long Beach, California, United States +94 more locations

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Leukemia Trials in Other Cities

DOSE Trial of Opioid Sparing Effect

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

AR101 Real-World Open-Label Extension Study

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Double Cord Versus Haploidentical (BMT CTN 1101)

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Study of AMV564 in Patients With AML

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Other Conditions in Portland